{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:56:07Z","timestamp":1776056167457,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Nonurothelial bladder cancer is rare, and there is no consensus regarding optimal systemic therapy. Even less well-defined is the role for surgical resection of oligometastatic sites that progress despite systemic therapy. Here, we describe the case of a 65-year-old woman who underwent radical cystectomy for locally advanced pure squamous cell carcinoma (SqCC) and subsequently developed two substantial metastatic lung lesions shortly after surgery. After her disease did not respond to platinum-based doublet chemotherapy and immunotherapy, hospice was considered, given her declining performance status. However, she underwent a pulmonary bilobectomy, which resulted in a durable complete response lasting over 2 years. This case demonstrates a potential role for surgical intervention in the management of metastatic SqCC of the bladder.<\/jats:p>","DOI":"10.3389\/fonc.2026.1806454","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:38:10Z","timestamp":1776055090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical management of metastatic squamous cell carcinoma of the bladder: a case report and review of the literature"],"prefix":"10.3389","volume":"16","author":[{"given":"Michael","family":"Schwartz","sequence":"first","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Hartman","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"McClintock","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishree","family":"Jagirdar","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Harik","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Oza","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Narayan","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline T.","family":"Brown","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"Martin","year":"2016","journal-title":"Arab J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_432054","article-title":"Advancements in urothelial cancer care: Optimizing treatment for your patient","volume":"44","author":"Hemenway","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.critrevonc.2019.01.008","article-title":"Biomarkers in non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review","volume":"135","author":"Maia","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_438640","article-title":"Current advances in the management of nonurothelial subtypes of bladder cancer","volume":"44","author":"Vlachou","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01409-x","article-title":"Squamous cell carcinoma of the bladder: Poor response to neoadjuvant chemotherapy","volume":"24","author":"Dotson","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)59330-1","article-title":"Squamous carcinoma of the bladder: Treatment by radical cystectomy","volume":"115","author":"Richie","year":"1976","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.urology.2006.08.1107","article-title":"Nonurothelial cancer of the bladder","volume":"69","author":"Abol-Enein","year":"2007","journal-title":"Urology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534858","article-title":"Metastatic squamous cell carcinoma of the urinary bladder: Urgent call for new therapies","volume":"108","author":"Banek","year":"2024","journal-title":"Urol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2\u2013positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/jco.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30907","article-title":"MP34\u201311 neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"197","author":"Vetterlein","year":"2017","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907454","article-title":"Neoadjuvant and adjuvant chemotherapy for variant histology bladder cancers: A systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.4591","article-title":"Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: A randomized phase 2 trial","volume":"153","author":"Zaghloul","year":"2018","journal-title":"JAMA Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.524","article-title":"Prospective trial of adjuvant therapy after radical cystectomy for locally advanced bladder cancer: Analysis of the squamous cell carcinoma subgroup","volume":"38","author":"Zaghloul","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.10.029","article-title":"Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract","volume":"69","author":"Galsky","year":"2007","journal-title":"Urology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.514","article-title":"A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract","volume":"38","author":"Sarfaty","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.03.019","article-title":"A complete response after pseudo-progression: Pembrolizumab for metastatic squamous cell carcinoma (SCC) of the bladder","volume":"17","author":"Kao","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: Implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.529","article-title":"Expression of nectin-4 and PD-L1 in bladder cancer with variant histology","volume":"40","author":"Case","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.652","article-title":"Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study","volume":"42","author":"Jindal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae161","article-title":"Trop-2 and ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes","volume":"163","author":"Case","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.4566","article-title":"Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b\/2 study","volume":"41","author":"Sheng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11903","article-title":"Critical overview of HER2 assessement in bladder cancer: What is missing for a better therapeutic approach","volume":"37","author":"Cimpean","year":"2017","journal-title":"Anticancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.003","article-title":"Metastasis","volume":"186","author":"Gerstberger","year":"2023","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2025.05.003","article-title":"The role of surgery for local consolidative therapy in the management of oligometastatic disease","author":"Jindani","year":"2025","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jtcvs.2020.02.134","article-title":"Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer","volume":"161","author":"Mitchell","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00658-8","article-title":"Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): A systematic review and individual patient data meta-analysis from the X-MET collaboration","volume":"27","author":"Tang","year":"2026","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.03.011","article-title":"Metastasis-directed therapy in the management of urothelial carcinoma: A systematic review and meta-analysis","volume":"11","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000542982","article-title":"Outcomes of surgical therapy for local recurrence and oligometastatic urothelial carcinoma of the bladder: 20 years of experience in a tertiary center","volume":"109","author":"Al-Nader","year":"2024","journal-title":"Urol Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.04.013","article-title":"Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: A systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"881.e15","DOI":"10.1016\/j.urology.2005.04.024","article-title":"Surgery for isolated lung metastasis in two patients with bladder cancer","volume":"66","author":"Tanis","year":"2005","journal-title":"Urology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:38:15Z","timestamp":1776055095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1806454"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1806454","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1806454"}}